glp-1/gip/glucagon receptor agonist GLP1-GIP co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica glp 1 and gip glp
Description
All studies have the percent change from randomization in body weight as the primary endpoint (8285)
Projected Evolution of GLP-1RA Use The growing interest in and diverse applications of GLP-1RAs are driving a substantial increase in the drugs user base
The medication regimen and medication-taking behavior should be reevaluated at regular intervals (every 3-6 months) and adjusted as needed to incorporate specific factors that impact the choice of treatment
Hoyer S
doi:10.1074/jbc.R113.534743 57
